<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327144</url>
  </required_header>
  <id_info>
    <org_study_id>F500EMS1010</org_study_id>
    <nct_id>NCT01327144</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 500 mg Comparing To Aciclovir 400mg in Patients With Herpes Zoster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Herpes Zoster is an infection that affects part of the nervous system caused by Varicella
      Zoster Virus. Herpes Zoster manifests as vesicular eruption in the dermatome, often
      associated with significant pain.

      There are effective oral prescription antiviral medicines available to reduce the discomfort
      of symptoms as famciclovir and aciclovir.

      This is a phase III, multicenter, randomized, parallel-group study to compare the efficacy
      and safety of treatment with Famciclovir (500 mg) comparing to Aciclovir (400 mg) in patients
      with Herpes Zoster.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design

        -  single blind study, prospective, parallel group, intent to treat trial

        -  Experiment duration: 7 days

        -  2 visits (days 0, and 7)

        -  Reduction of symptoms

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For efficacy evaluation, a visual analogue scale (VAS) will be used to detect the improvement of symptoms</measure>
    <time_frame>day 7</time_frame>
    <description>Symptoms evaluated: pain, injury, loss of sensation, burning and itching</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>day 7</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Famciclovir 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet each 8 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aciclovir 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets of Aciclovir 400 mg each 4 hours for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famciclovir</intervention_name>
    <description>Famciclovir 500 mg- 1 tablet each 12 hours for 7 days</description>
    <arm_group_label>Famciclovir 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aciclovir</intervention_name>
    <description>Aciclovir 400 mg- 02 tablets each 4 hours for 7 days</description>
    <arm_group_label>Aciclovir 400mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be able to understand the study procedures, agree to participate and
             give written consent.

          -  Patients with clinical diagnosis of Herpes Zoster;

          -  Score higher than 4 for at least for 2 symptoms of Herpes Zoster;

          -  Negative pregnant urine test

        Exclusion Criteria:

          -  Pregnancy or risk of pregnancy.

          -  Lactation

          -  Any pathology or past medical condition that can interfere with this protocol.

          -  Non-steroidal anti-inflammatory drug , hormonal anti-inflammatory or immunosuppressive
             drugs (in the last 30 days and during the study);

          -  Patients with immunodeficiency and/or immunosuppressive disease;

          -  Hypersensitivity to components of the formula;

          -  Other conditions deemed reasonable by the medical investigator as to the
             disqualification of the individual from study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce Silva, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pesquisa Clinica</last_name>
    <phone>55 11 38879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Medicina Reprodutiva Dr Carlos Isaia Filho</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Isaia Filho, MD</last_name>
      <phone>55 51 3222-8180</phone>
    </contact>
    <investigator>
      <last_name>Carlos Isaia Filho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loema</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13010001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio R Santos, MD</last_name>
      <email>contato@loemaipc.com.br</email>
    </contact>
    <investigator>
      <last_name>Fabio R Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CECIP Centro de Estudos Clínicos do Interior Paulista</name>
      <address>
        <city>Jau</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula U. Tokunaga, MD</last_name>
      <email>cecipjau@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paula U. Tokunaga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Afip - Associacao Fundo de Incentivo A Pesquisa</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Tomimori, MD</last_name>
      <phone>55 11 5908 7081</phone>
    </contact>
    <investigator>
      <last_name>Jane Tomimori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre L Vergnanini, MD</last_name>
      <phone>+55193789-8600</phone>
    </contact>
    <investigator>
      <last_name>André L Vergnanini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Famciclovir</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

